Syndax halts IPF development: Wainwright keeps USD 38 target for Syndax Pharmaceuticals stock

Published on 10/20/2026 at 13:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 72.79 million. Syndax Pharmaceuticals stock costs EUR 11.71 on October 20, 2026 before November 2 results.

Trial development and revenue

MAXPIRe enrolled 145 patients before Syndax ended its IPF development plan on October 12, 2026.
Second-quarter 2026 revenue rose 92 percent year over year to USD 72.79 million.
Syndax Pharmaceuticals stock traded at EUR 11.71 at 1:37 p.m. CEST at Lang & Schwarz on October 20, 2026.
The next earnings date is November 2, 2026.

SNDX, US87164F1057, Illustration mit AI erstellt.

Syndax Pharmaceuticals (ISIN US87164F1057) was trading at EUR 11.71 at Lang & Schwarz on October 20, 2026, while its latest clinical setback reshaped the pipeline. On October 12, 2026, Syndax Pharmaceuticals said its Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint. The result ended further development in that indication, although the company said ongoing chronic graft-versus-host disease trials were unaffected.

Pipeline setback carries a clear number

MAXPIRe was a 26-week trial with 145 patients across 62 sites in 14 countries. The primary endpoint was the annualized rate of decline in forced vital capacity, a lung-function measure. Syndax reported that axatilimab was well tolerated and that no new safety signals emerged, but the missed endpoint removes one development path for the drug.

The commercial business provides a more supportive counterweight. According to Investing.com, second-quarter 2026 revenue increased 92 percent from the prior year to USD 72.8 million, including USD 54.7 million from Revuforj and USD 18.1 million in collaboration revenue from Niktimvo. The same report said BofA Securities cut its target to USD 26 and UBS reduced its target to USD 33, showing that the pipeline setback arrived alongside a more demanding valuation debate.

Three dated developments for SNDX

On October 12, 2026, the 145-patient MAXPIRe trial missed its primary endpoint, according to Syndax Pharmaceuticals. On October 13, 2026, H.C. Wainwright maintained its Buy rating and USD 38.00 target, as reported by Yahoo Finance. On October 15, 2026, Revuforj was named to TIME's Best Inventions of 2026 list, according to GlobeNewswire.

What comes next for the company

The next scheduled reporting date is November 2, 2026, according to Yahoo Finance. Investors will have two competing figures to weigh: second-quarter 2026 revenue of USD 72.79 million and a consolidated net loss of USD 49.36 million. The revenue base is expanding, but the failed IPF study narrows the evidence supporting future growth beyond the approved oncology and chronic graft-versus-host disease products.

Price stays tied to the pipeline debate

Syndax Pharmaceuticals was trading at EUR 11.71 at Lang & Schwarz on October 20, 2026 at 1:37 p.m. CEST. The next catalyst is the November 2, 2026 reporting date, when investors can assess commercial performance alongside the remaining clinical program.

The further course of trading is shown by the continuously updated real-time quote of Syndax Pharmaceuticals stock.